(0.31%) 5 115.59 points
(0.31%) 38 358 points
(0.34%) 15 982 points
(-0.87%) $83.12
(5.77%) $2.03
(0.39%) $2 356.40
(0.50%) $27.67
(4.05%) $959.45
(-0.22%) $0.933
(-0.39%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...
Stats | |
---|---|
本日の出来高 | 15 631.00 |
平均出来高 | 132 512 |
時価総額 | 42.70M |
EPS | $0 ( 2024-04-03 ) |
次の収益日 | ( $-0.510 ) 2024-05-09 |
Last Dividend | $0.0900 ( 2014-08-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.610 |
ATR14 | $0.0170 (1.53%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Yonehiro Grant | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Perez Edith A. | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Schatzman Randall C | Buy | 654 000 | Stock Option (Right to Buy) |
2024-03-04 | Quinn William P. | Buy | 235 000 | Stock Option (Right to Buy) |
2023-12-31 | Yonehiro Grant | Buy | 0 |
INSIDER POWER |
---|
72.73 |
Last 93 transactions |
Buy: 5 349 325 | Sell: 1 125 168 |
Bolt Biotherapeutics, 財務諸表
Annual | 2023 |
収益: | $7.88M |
総利益: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2023 |
収益: | $7.88M |
総利益: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2022 |
収益: | $5.73M |
総利益: | $838 000 (14.63 %) |
EPS: | $-2.30 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.97 |
Financial Reports:
No articles found.
Bolt Biotherapeutics, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2012-03-06 |
Last Dividend | $0.0900 | 2014-08-29 |
Next Dividend | $0 | N/A |
Payout Date | 2014-10-02 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.830 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0.326 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.424 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.501 | 1.500 | -6.68 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.06 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.528 | 1.500 | 8.18 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 53.10 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.919 | -1.838 | [0 - 20] |
debtEquityRatioTTM | 0.179 | -1.500 | 9.28 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.577 | 1.000 | 3.72 | 3.72 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.67 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0493 | 0.800 | -3.00 | -2.40 | [0.5 - 2] |
Total Score | 0.326 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.622 | 1.000 | -0.164 | 0 | [1 - 100] |
returnOnEquityTTM | -0.501 | 2.50 | -4.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.613 | -1.838 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00463 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -8.83 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.76 |
Bolt Biotherapeutics,
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。